PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
15.87%
Revenue growth of 15.87% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
24.23%
Gross profit growth of 24.23% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
40.42%
EBIT growth of 40.42% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
40.42%
Operating income growth of 40.42% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
35321.48%
Net income growth of 35321.48% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
15900.00%
EPS growth of 15900.00% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
18.67%
Share change of 18.67% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
-3.21%
Diluted share reduction while Healthcare median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
189.60%
OCF growth of 189.60% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
78.29%
FCF growth of 78.29% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
425.89%
OCF/share CAGR of 425.89% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
425.89%
OCF/share CAGR of 425.89% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
189.34%
3Y OCF/share growth of 189.34% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
406.73%
Net income/share CAGR of 406.73% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
406.73%
Net income/share CAGR of 406.73% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
1531.95%
3Y net income/share CAGR > 1.5x Healthcare median of 2.50%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
340.60%
Equity/share CAGR of 340.60% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
340.60%
5Y equity/share CAGR > 1.5x Healthcare median of 8.45%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
407.04%
3Y equity/share CAGR > 1.5x Healthcare median of 9.57%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.97%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
18.67%
Inventory growth of 18.67% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
28.78%
Asset growth of 28.78% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
10.83%
BV/share growth of 10.83% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
No Data
No Data available this quarter, please select a different quarter.
-89.14%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
24.88%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.